Gilead Rises with Acquisition, Novo Nordisk GLP1 Drops, Domino's Cooks

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Gilead Sciences Inc. agreed to buy US cancer-focused biotech Arcellx Inc. for as much as $7.8 billion as it seeks to boost its drug pipeline. Gilead, which owns 11.5% of Arcellx’s outstanding stock, will pay $115 per share in cash, with a contingent payment of $5 per share dependent on future sales, it said Monday. The price is almost double Arcellx’s Friday closing price. Shares of Arcellx rose as much as 78% to $114.18 in premarket trading in New York, while Gilead’s stock slipped about 0.6%. - Novo Nordisk A/S’s next-generation obesity shot delivered less weight loss than Eli Lilly & Co.’s rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Novo’s shares plunged as much as 16.5% in Copenhagen on Monday, while Lilly shares rose as much as 4.2% in premarket US trading. - Domino's Pizza posted another quarter with strong comparable-sales growth and new restaurant openings, which sent the stock higher Monday. Still, shares have been trading at their lowest levels in more than two years as investors remain cautious about the restaurant sector. For the fourth quarter ended in December, the pizza chain grew its net revenue by 6.4% from a year ago to $1.54 billion, beating Wall Street's consensus expectations of $1.52 billion. Earnings came in at $5.35 per share, up 9.4% from a year earlier, but slightly below the expected $5.38, the company said Monday.See omnystudio.com/listener for privacy information.